期刊文献+

半乳糖神经酰胺脂质体对HIV-1感染性的影响 被引量:7

Effects of galactosylceramide liposomes on HIV-1 infectivity
下载PDF
导出
摘要 目的 研究体外空白及包封抗HIV药物AZT和PFA 的GalCer脂质体 对HIV-1复制的影响。方法 通过HIV p24抗原测定、合胞体抑制实验、 融合阻断实验和对HIV感染细胞的保护作用实验等,观察了空白GalCer脂质体、 AZT-GalCe r脂质体和PFA-GalCer脂质体对HIV-1复制的影响。 结果空白GalCer脂 质体预处理细胞,能促进HIV-1感染CD4+ 细胞;空白GalCer脂质体预处理HIV-1,则抑 制了病毒吸附和结合宿主细胞;GalCer脂质体还具有阻断HIV-1感染细胞与正常CD4+细胞 间的融合作用;GalCer脂质体包封AZT或PFA不能显著提高药物体外抗HIV-1活性。 结论 空白GalCer脂质体预处理细胞,能促进HIV-1感染性;预处理HIV-1,则 抑制了病毒的感染。 Objective To study effects of free and GalCer liposome-encapsulated azidothymidine(AZT) and foscarnet(PFA) on HIV-1 infectivity. Methods Level of HIV-1 p24 antigen, inhibition of syncytium formation, blockage of fusion and protection of HIV-1 infected cells were detected. Results The preincubation of C8166 cells with drug-free liposomes enhanced virus production, and while pretreatment of HIV-1 with drug-free liposomes, the attachment and binding of HIV-1 to cells were markedly inhibited. Liposomes also inhibit membrane fusion between C8166 cells and HIV-1ⅢB chronically infected H9 cells. The liposomal AZT and liposomal PFA gave simila ranti-HIV-1 efficacy compared to free drugs. Conclusion The preincubation of C8166 cells with drug-free liposomes enhanced virus production. While pretreatment of HIV-1 with drug-free liposomes, HIV-1 infectivity was markedly inhibited.
出处 《免疫学杂志》 CAS CSCD 北大核心 2002年第2期128-131,共4页 Immunological Journal
基金 云南省自然科学研究基金(1999C0087M) 卫生部科学研究基金(98-1-336) 云南省中青年科学与技术学术带头人基金(95-12) 中国科学院
关键词 半乳糖神经酰胺 脂质体 HIV-1 药物载体 病毒感染 免疫缺陷病毒 galactosylceramide liposome HIV-1 AZT foscarnet
  • 相关文献

参考文献3

二级参考文献30

  • 1郑永唐,贲昆龙.抗人类免疫缺陷病毒药物的研究进展[J].大自然探索,1998(4):80-86. 被引量:5
  • 2[7]Harvie P, Desormeaux A, Gagne N, et al. Lymphoid tissues targeting of liposome-encapsulated 2' 3 '-dideoxyinosine (ddI) [J]. AIDS, 1995, 9(7):701- 707.
  • 3[8]Dusserre N, Lessard C, Paquette N, et al. Encapsulation of foscamet in liposomes modifies drug intracellular accumulation, in vitro anti HIV-1 activity, tissue distribution, and pharmacokinetics [J]. AIDS, 1995, 9(8) :833 - 841.
  • 4[9]Huwvler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes [J]. Proc Natl Acad Sci USA, 1996,93(24):14 164- 14 169.
  • 5[10]Kim S, Scheerer S, Geyer MA, et al. Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes [J]. J Infect Dis, 1990,162(3) :750- 752.
  • 6[11]Oussoren C, Magnani M, Fraternale A, et al. Liposomes as carriers of the antiretroviral agent dideoxycytidine-5'-triphosphate [J]. Int J Pharm, 1999,180(2) :261 - 270.
  • 7[12]Desormeaux A, Harvie P, Perron S, et al. Antiviral efficacy intracellular uptake and tissue distribution of liposome-encapsulated 2', 3'-dideoxyinosine (ddI) in rats [J]. AIDS,1994,8(11):1 545-1 553.
  • 8[13]Makabi Panzu B, Lessard C, Parron S, et al. Comparison of cellular accumulation, tissue distribution and anti-HIV activity of free and liposomal 2', 3'-dideoxycytidine [J]. AIDS Res Hum Retroviruses, 1994,10(11):1 463- 1 470.
  • 9[14]Pretzer E, Flasher D, Duzgunes N. Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease [J]. Antiviral Res, 1997,34(1):1 - 15.
  • 10[15]Slepushkin VA, Simoes S, Dazin P, et al. Sterically stabilized pH sensitive liposomes: Intracellular delivery of aqueous contents and prolonged circulation in vivo [J]. J Biol Chem,1997,272(4) :2 382 - 2 388.

共引文献217

同被引文献38

  • 1周怡,席瑜钦.儿童疫苗的现状、问题及研究进展[J].中国处方药,2005(2):34-38. 被引量:2
  • 2雷杰杰,邓意辉,陈国良,金圣煊,毕殿洲.RP-HPLC测定齐多夫定棕榈酸酯脂质体药物含量[J].中国药学杂志,2005,40(7):538-540. 被引量:10
  • 3王鲁平,朱永珙.齐多夫定对获得性免疫缺陷综合征的治疗作用和不良反应[J].新药与临床,1996,15(1):38-40. 被引量:9
  • 4徐叔云 张树臣 见:徐叔云 卞如濂 陈修主编.全身性毒性[A].见:徐叔云,卞如濂,陈修主编.药理实验方法学[C].北京:人民卫生出版社,1991.201~3.
  • 5马培奇.艾滋病治疗药物最近进展[J].上海医药情报研究,1997(1):7-10. 被引量:6
  • 6Chan D C, Fass D, Berger J M, et al. Core structure of gp41 from the HIV envelope glycoprotein[J]. Cell, 1997,B9: 263.
  • 7Jiang S, Lin K, Zhang L, et al. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody[J]. J Virol Methods, 1999,80 : 85.
  • 8Debnath A K, Lin K, Jiang S. Structure-based identification of small molecule antiviraI compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1 [J]. J Med Chem, 1999,42:3203.
  • 9Eckert D M, Malashkevich V N, Hong I. H, et al. Inhibiting HIV-1 Entry: Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket[J]. Cell, 1999,99 : 103.
  • 10Daria J, Hazuda P F, Wjtmer M,et al.Inhihitors of strand transfer that prevent integration and inhibit HIV-integase catalytic domain complexed with an inhibitorfa platform for antiviral drug design [J]. Proc Natl Acad Sci USA, 1999,96 : 13040.

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部